Intravenous immunoglobulin G (
IVIg) is widely used against a range of clinical symptoms. For its use in immune modulating
therapies such as treatment of
immune thrombocytopenic purpura high doses of
IVIg are required. It has been suggested that only a fraction of
IVIg causes this anti immune modulating effect. Recent studies indicated that this fraction is the Fc-sialylated
IgG fraction. The aim of our study was to determine the efficacy of
IVIg enriched for sialylated
IgG (
IVIg-SA⁺) in a murine model of passive
immune thrombocytopenia (PIT). We enriched
IVIg for sialylated
IgG by Sambucus nigra
agglutinin (SNA)
lectin fractionation and determined the degree of sialylation. Analysis of
IVIg-SA⁺ using a
lectin-based ELISA revealed that we enriched predominantly for Fab-sialylated
IgG, whereas we did not find an increase in Fc-sialylated
IgG. Mass spectrometric analysis confirmed that Fc sialylation did not change after SNA
lectin fractionation. The efficacy of sialylated
IgG was measured by administering
IVIg or
IVIg-SA⁺ 24 hours prior to an injection of a rat anti-mouse platelet mAb. We found an 85% decrease in platelet count after injection of an anti-platelet mAb, which was reduced to a 70% decrease by injecting
IVIg (p<0.01). In contrast,
IVIg-SA⁺ had no effect on the platelet count. Serum levels of
IVIg and
IVIg-SA⁺ were similar, ruling out enhanced
IgG clearance as a possible explanation. Our results indicate that SNA
lectin fractionation is not a suitable method to enrich
IVIg for Fc-sialylated
IgG. The use of
IVIg enriched for Fab-sialylated
IgG abolishes the efficacy of
IVIg in the murine PIT model.